| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
In this research, budded recombinant baculovirus vectors (BVs) have been developed because BVs have many advantages for tissue targeting gene delivery vectors.It is easily possible to display exogenous proteins on the surface of BV virion. CSP and TRAP, malaria sporozoite surface proteins have highly selective affinity to hepatocytes. BVs expressing CSP or TRAP molecule on the virion surface have been constructed and they were shown to greatly increase transduction efficacy to human hepatoma cell line (HepG2 et al.) and human primary hepatocytes (PXB cells). Furthermore, to overcome the vulnerability to serum complement system, fusion molecules of complement regulatory proteins were displayed to BV virion surfaces. These BVs were shown to greatly increase resistance against complement attack.
|
